STOCK TITAN

Black Diamond Therapeutics, Inc. - BDTX STOCK NEWS

Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a leading precision oncology medicine company headquartered in Cambridge, Massachusetts. Founded in 2014, the company focuses on the discovery and development of small molecule, tumor-agnostic therapies designed to target families of oncogenic mutations across various cancers.

The core of Black Diamond’s innovative approach lies in its proprietary Mutation-Allostery-Pharmacology (MAP) platform. This platform enables the identification and targeting of allosteric mutations in key cancer-related kinases, offering new therapeutic options for patients with limited treatments available.

The company’s lead product candidate, BDTX-189, is a potent inhibitor targeting non-canonical and oncogenic mutations of ERBB kinases, including the epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The development pipeline also includes BDTX-1535, an advanced fourth-generation EGFR inhibitor, and BDTX-4933, targeting KRAS, NRAS, and BRAF mutations in solid tumors.

Recent clinical updates highlight the potential of BDTX-1535 in treating non-small cell lung cancer (NSCLC) and glioblastoma (GBM), demonstrating efficacy against over 50 clinically relevant non-classical EGFR mutations and resistance mutations like C797S. This candidate is currently advancing through Phase 2 trials, with promising results expected in 2024.

Black Diamond Therapeutics has also established significant collaborations and partnerships to bolster its research and development efforts. These collaborations aim to enhance the understanding of mutation landscapes and accelerate the delivery of new therapies to patients.

For more information, visit Black Diamond Therapeutics.

Rhea-AI Summary

Black Diamond Therapeutics announced the appointment of Rachel Humphrey, M.D. as Chief Medical Officer, effective immediately. Dr. Humphrey succeeds Karsten Witt, M.D., who will now serve as Senior Vice President of Non-Clinical Development. With extensive experience in oncology drug development, Dr. Humphrey joins from CytomX Therapeutics and has held senior roles at major pharmaceutical companies. Her leadership is expected to enhance the development of BDTX-189, an innovative inhibitor targeting oncogenic mutations across various cancers, which currently lacks a comparable FDA-approved treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
management
-
Rhea-AI Summary

Black Diamond Therapeutics (BDTX) announced significant advancements regarding its lead candidate, BDTX-189, receiving FDA Fast Track designation for treating adult patients with specific solid tumors. The Phase 1/2 clinical trial is progressing as scheduled, with completion expected by mid-2021. Financially, the company reported a strong cash position of $345.0 million as of June 30, 2020, up from $39.7 million in Q2 2019. R&D expenses rose to $10.2 million, influenced by the trial's development, while G&A expenses also increased to $4.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Summary

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a leader in precision oncology, announced that CEO David M. Epstein will present at two upcoming investor conferences. The presentations are scheduled for August 12, 2020, at the Wedbush PacGrow Healthcare Conference and August 13, 2020, at the Canaccord Genuity Growth Conference. Live webcasts will be available on the company’s website, with replays archived for three weeks. Black Diamond focuses on developing tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) has appointed Fang Ni, Pharm.D., as Chief Business Officer. Ni, who has previously served as interim CBO and possesses extensive expertise in business development, is expected to lead strategic initiatives to advance the company’s clinical pipeline. He is credited with contributions to Black Diamond's corporate strategies and has a solid background in oncology from his tenure at Roche and Versant Ventures. The leadership change is aimed at capitalizing on Black Diamond's innovative MAP platform for drug discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
management
-
Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced FDA's Fast Track designation for BDTX-189, targeting adult patients with solid tumors harboring specific mutations. This designation aims to expedite the development of BDTX-189, an orally available small molecule inhibitor, which addresses unmet needs in cancer therapy. The drug is currently undergoing evaluation in the MasterKey-01 Phase 1/2 clinical trial, assessing its safety and effectiveness in patients with advanced solid tumors. The Fast Track status allows for closer collaboration with the FDA and a potential accelerated approval process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
Rhea-AI Summary

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced that CEO David M. Epstein, Ph.D., will present a business update at the BMO 2020 Healthcare Conference on June 23, 2020, at 2:00 PM ET. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for three weeks. Black Diamond focuses on precision oncology and aims to develop small molecule, tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers using its proprietary MAP technology platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
Rhea-AI Summary

Black Diamond Therapeutics, a precision oncology company, announced that its CEO, David M. Epstein, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:30 PM ET. The presentation will cover the company's advancements in tumor-agnostic therapies, targeting undrugged mutations in cancers. Investors can access a live webcast and replay on the company’s website for three weeks. Black Diamond's MAP platform allows for the development of tailored therapies based on genetic data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences
-
Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that the MasterKey-01 clinical trial design for BDTX-189, its lead product candidate, will be presented at the ASCO 2020 Virtual Scientific Program from May 29-31, 2020. This Phase 1/2 trial aims to assess the safety, tolerability, pharmacokinetics, and anti-tumor activity of BDTX-189 in patients with advanced solid tumors. It targets mutations in the ErbB family of proteins. With no FDA-approved therapies for these mutations existing, BDTX-189 could represent a significant advancement in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) reported Q1 2020 financials, highlighting $357.2 million in cash and equivalents. The initial public offering in February raised $231.3 million, bolstering their position to fund operations through 2023. The Phase 1/2 clinical trial for BDTX-189, their lead therapy, is ongoing, with completion expected in the first half of 2021. Operating expenses have increased, with R&D expenses at $7.4 million and G&A expenses at $5.5 million due to increased personnel and public company costs. The net loss for the quarter was $12.1 million, reflecting continued investment in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present a business update at the Bank of America Global Research Health Care Conference 2020. The presentation is scheduled for May 12, 2020, at 4:20 PM ET. Black Diamond is focused on developing small molecule, tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers. Their proprietary Mutation-Allostery-Pharmacology (MAP) platform enables the analysis of genetic data to create therapies for specific mutation families.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences

FAQ

What is the current stock price of Black Diamond Therapeutics (BDTX)?

The current stock price of Black Diamond Therapeutics (BDTX) is $2.13 as of January 6, 2025.

What is the market cap of Black Diamond Therapeutics (BDTX)?

The market cap of Black Diamond Therapeutics (BDTX) is approximately 126.8M.

What does Black Diamond Therapeutics do?

Black Diamond Therapeutics focuses on discovering and developing precision oncology therapies targeting oncogenic mutations in cancer.

Where is Black Diamond Therapeutics headquartered?

The company is headquartered in Cambridge, Massachusetts.

What is the Mutation-Allostery-Pharmacology (MAP) platform?

The MAP platform enables the identification and targeting of allosteric mutations in cancer-related kinases.

What is BDTX-189?

BDTX-189 is Black Diamond’s lead product candidate, targeting non-canonical and oncogenic mutations of ERBB kinases.

What are the key clinical-stage programs at Black Diamond?

The company is advancing BDTX-1535, an EGFR inhibitor, and BDTX-4933, targeting KRAS, NRAS, and BRAF mutations.

What recent achievements has Black Diamond Therapeutics made?

The company presented promising preclinical and clinical data for BDTX-1535 at major scientific meetings and is progressing to Phase 2 trials.

What are upcoming milestones for Black Diamond Therapeutics?

Key milestones include initial results from Phase 2 trials for BDTX-1535 in NSCLC expected in Q3 2024.

What collaborations is Black Diamond involved in?

The company has formed significant partnerships to enhance mutation research and accelerate therapy development.

When was Black Diamond Therapeutics founded?

The company was founded in 2014.

How does BDTX-1535 differ from existing therapies?

BDTX-1535 is designed to inhibit a broad spectrum of over 50 non-classical EGFR mutations and the C797S resistance mutation, offering potential benefits over current therapies.
Black Diamond Therapeutics, Inc.

Nasdaq:BDTX

BDTX Rankings

BDTX Stock Data

126.75M
55.24M
2.29%
98.73%
11.31%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE